

What is Amarin's view on the reliability of third-party script reporting services?

Companies such as IQVIA and Symphony Health collect and report estimates of weekly, monthly, quarterly and annual prescription information. There is a limited amount of information available to such companies to determine the actual number of total prescriptions for prescription products like Vascepa during such periods. Estimates are based on a combination of data received from pharmacies and other distributors, and historical data when actual data is unavailable. Calculations can be significantly affected by lags in data reporting from various sources or by changes in pharmacies and other distributors providing data. Such methods can from time to time result in material inaccuracies in information when ultimately compared with actual results. These inaccuracies have historically been most prevalent and pronounced during periods of time of inflections upward or downward in rates of use. Further, data for a single and limited period may not be representative of a trend or otherwise predictive of future results. And, data reported by IQVIA and Symphony Health is rarely identical. As such, the resulting conclusions from such sources should be viewed with caution. Amarin is not responsible for the accuracy of these companies' information and Amarin does not receive prescription data directly from retail pharmacies.

As a reminder, Amarin sells Vascepa principally to a limited number of major wholesalers, as well as selected regional wholesalers and specialty pharmacy providers in the United States, or collectively, its distributors or its customers, that in turn resell Vascepa to retail pharmacies for subsequent resale to patients and healthcare providers. Amarin recognizes revenues from product sales when the distributor obtains control of Amarin's product, which occurs at a point in time, typically upon delivery to the distributor. These amounts are not impacted by reporting from Symphony Health or IQVIA. Amarin plans to report financial results quarterly, for example, in quarterly reports on Form 10-Q and related press releases, in the ordinary course after Amarin's auditors complete their customary review.

Posted on June 28, 2019